NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









KSQ Therapeutics

KSQ Therapeutics

Private
Lexington, MassachusettsHealthcare & Life Scienceshttps://ksqtx.com/

Last Round

Series C

Sep 28, 2018

Total Funding Raised

$156M

Company Overview

KSQ Therapeutics is a clinical-stage biotechnology company that utilizes its proprietary CRISPRomics® discovery engine to identify novel drug targets and develop treatments for solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

CRISPRfunctional genomicsdrug discoveryprecision medicinecell therapyoncologyautoimmune diseasetherapeutic targetscomputational biologybioinformaticsbiotechgenome screeningsmall moleculedrug developmentgenomics platform

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

KSQ Therapeutics Comparables

Compare KSQ Therapeutics with similar companies based on industry and business-model similarity.

KSQ Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Tango Therapeutics
81%
Maze Therapeutics
80%
Repare Therapeutics
77%

KSQ Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CSep 28, 2018
Series BOct 2, 2017
SeedOct 1, 2015

Key People

Founding team and executive leadership

Qasim Rizvi

Chief Executive Officer

Executive Team

Thomas Leitch

Chief Technology Officer

Executive Team

Chris Heberlig

Chief Financial Officer

Executive Team

KSQ Therapeutics Investors

Notable investors and investment history

KSQ Therapeutics investors
InvestorRounds
Cowen Private InvestmentsSeries C
ARCH Venture PartnersSeries B, Series C
Blue Owl CapitalSeries C
Invus OpportunitiesSeries C
ARCH Venture PartnersSeries B, Series C
Alexandria Venture InvestmentsSeries B, Series C
Lilly Asia VenturesSeries C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 5, 2025

    Kristen Hege, M.D. appointed to the Board of Directors.

KSQ Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

KSQ Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about KSQ Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersLexington, Massachusetts
Employee Range58
Year Founded2015
Last FundingSep 28, 2018

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.